Pandemic Preparedness & Disease X (UPSC Science & Tech)
UPSC guide to Disease X, India's pandemic preparedness: PM-ABHIM, IHR 2005, Pandemic Treaty, One Health, INSACOG, and 2024-26 updates.
“Disease X” is the WHO’s placeholder term for the next unknown pathogen that could cause a serious international epidemic. The COVID-19 pandemic proved that such a disease is not science fiction — and next time it could be worse. India, scarred by 2020-22, is now investing in surveillance, vaccines, hospital capacity, one-health coordination and global governance reforms. For UPSC, this is a frequently-tested topic across GS Paper III (Science & Tech, Disaster Management) and GS Paper II (Health Governance, International Relations).
What is Disease X?
The WHO's R&D Blueprint Priority Pathogens list identifies diseases with epidemic potential but limited or no counter-measures — including Ebola, Marburg, Lassa, Nipah, MERS-CoV, SARS, Crimean-Congo hemorrhagic fever, Rift Valley fever, and "Disease X", a reserved slot for an unknown future threat.
Disease X characteristics assumed:
- Zoonotic origin — from bats, rodents, primates or livestock.
- Respiratory or vector-borne transmission.
- High R₀ — rapid human-to-human spread.
- Case fatality ratio uncertain (could be much higher than SARS-CoV-2).
- No existing vaccine, limited diagnostics.
Candidates often discussed: a novel influenza strain (H5N1 reassortant), another sarbecovirus, a new henipavirus, prion, or antifungal-resistant fungus.
Drivers of spill-over and spread
| Driver | Detail |
|---|---|
| Deforestation & land-use change | Expanding wildlife-human interface |
| Wet markets & wildlife trade | Mixing species concentrates risk |
| Factory farming | Dense livestock populations breed pathogens |
| Antimicrobial & antiviral resistance | Erodes first-line defences |
| Climate change | Shifts vector distribution (Aedes, Anopheles) |
| Urbanisation & slums | Dense populations with poor WASH |
| Global air travel | Hours between outbreaks and pandemics |
| Lab safety lapses | Biosafety Level breaches, dual-use research of concern |
| Conflicts & displacement | Disrupt vaccination and surveillance |
Lessons from COVID-19 (2019-23)
- Speed of science: mRNA vaccines developed in 11 months from genome to deployment.
- Global scale-up: Serum Institute became backbone of COVAX via Covishield and Covovax.
- Diagnostics: RT-PCR and rapid antigen testing scaled rapidly.
- Digital platforms: CoWIN (India), Aarogya Setu — mass public-health infra.
- INSACOG consortium — India's genomic surveillance of SARS-CoV-2.
- Failures: oxygen shortage in Delta wave, vaccine nationalism, data opacity.
- Cost: IMF estimated COVID set back global GDP by $28 trillion.
India's pandemic-preparedness architecture
Institutional
| Body | Role |
|---|---|
| Ministry of Health & Family Welfare (MoHFW) | Apex |
| Integrated Disease Surveillance Programme (IDSP) | NCDC-led daily surveillance |
| ICMR | Biomedical research, epidemiology |
| NCDC | Outbreak response |
| INSACOG | Genomic consortium — 50+ labs |
| NIV Pune, NIMHANS, NIRT Chennai, NIE | Reference and research |
| Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) | Insurance safety net |
| PM Ayushman Bharat Health Infrastructure Mission (PM-ABHIM, 2021) | Rs 64,180 crore; district labs, critical-care hospital blocks |
Legal
- Epidemic Diseases Act, 1897 (colonial); inadequate for modern challenges.
- Disaster Management Act, 2005 — main legal basis used in COVID-19.
- Drugs & Cosmetics Act, 1940; New Drugs and Clinical Trials Rules 2019.
- IT Rules and DPDP Act 2023 — for data aspects of digital health.
- Ayushman Bharat Digital Mission (ABDM) — digital health infrastructure.
Vaccines
- Mission Indradhanush / PMSM — routine immunisation.
- Universal Immunization Programme — 12 vaccines.
- Serum Institute of India — world's largest volume vaccine maker.
- Bharat Biotech, Biological E, Zydus, Panacea, Shantha — vaccine manufacturing depth.
- CEPI partnerships — pandemic prep funding.
- mRNA vaccine platforms — Gennova (HGCO19, approved 2022); scaling up.
Surveillance and diagnostics
- INSACOG — genomic sequencing for SARS-CoV-2 and expanding to other pathogens.
- IDSP and Integrated Health Information Platform (IHIP) — real-time surveillance.
- National Institute of One Health (NIOH), Nagpur — opened 2022.
- BSL-3 and BSL-4 labs — NIV Pune's BSL-4 is South Asia's only public BSL-4.
- ICMR's National Biosafety Support Unit.
Global governance
Present
- IHR 2005 — mandates reporting of public health emergencies of international concern (PHEIC).
- WHO — declares PHEIC (COVID-19, mpox 2022 & 2024).
- GPMB (Global Preparedness Monitoring Board) — annual report.
- Gavi, CEPI, FIND, UNICEF — pandemic infrastructure partners.
- Global Health Security Agenda (GHSA) — multilateral platform.
Emerging
- Pandemic Agreement (WHO) — negotiations began 2022 after COVID-19; targeted completion postponed; WHA 77 (May 2024) extended talks to WHA 78 (May 2025). Key issues: pathogen and benefit sharing, technology transfer, equitable access (PABS — Pathogen Access and Benefit-Sharing system), sovereignty concerns.
- IHR 2005 Amendments (June 2024) adopted: pandemic emergencies classification, equitable access provisions, financing mechanisms.
- Pandemic Fund (World Bank, 2022) — disburses for LMIC preparedness.
India's position
India has:
- Supported strong IHR amendments.
- Pushed for pathogen-sharing linked to benefit-sharing.
- Hosted One Health Leaders' Meeting during G20 Presidency (2023).
- Opposed extraterritorial WHO authority that could violate sovereignty.
One Health in India
- National One Health Mission (2023) — ICMR, DBT, MoEFCC, DAHD, MoHFW coordination.
- Cross-sectoral triggers: monitoring zoonoses, AMR, food safety, wildlife pathogens.
- National Institute of One Health (Nagpur) as a hub.
- ICMR's Bhopal Memorandum (2023) — One Health framework.
Key diseases to watch
| Pathogen | Risk profile |
|---|---|
| Nipah virus | High CFR; bat reservoir; Kerala outbreaks 2018, 2021, 2023 |
| Avian influenza (H5N1) | Resurgence in dairy cattle (USA 2024); human cases rising |
| Marburg virus | Rwanda outbreak 2024 |
| Ebola, Sudan ebolavirus | Uganda outbreak 2022; recurrent |
| Mpox (clades I & II) | PHEIC declared again Aug 2024 due to clade Ib |
| Crimean-Congo HF | Gujarat, Rajasthan cases |
| Zika, Chikungunya, Dengue | Urban Aedes-borne; climate-sensitive |
| Scrub typhus, JE, Kyasanur Forest Disease | Zoonotic endemic |
| Antifungal-resistant Candida auris | Hospital outbreaks |
Innovation frontier
- mRNA platform vaccines — rapid design for new pathogens.
- Self-amplifying RNA (saRNA) vaccines.
- Pan-coronavirus vaccines.
- AI-based pathogen surveillance — wastewater sequencing, social media signals.
- Metagenomic sequencing for unknown agents.
- Phage therapies for resistant bacteria.
- Broad-spectrum antivirals.
- CRISPR-based diagnostics (Sherlock, DETECTR, FELUDA — CSIR-IGIB's FELUDA approved for COVID in 2020).
Latest developments (2024-26)
- WHO IHR amendments adopted (June 2024) — pandemic emergency concept, equitable access, financing.
- Pandemic Agreement (2025) — target finalisation at WHA 78 (May 2025); key issues unresolved on PABS.
- Mpox PHEIC (Aug 2024) — clade Ib spread from DRC to multiple countries; India reported first case of clade Ib in early 2025.
- H5N1 in US dairy cattle (2024-25) — global surveillance stepped up.
- Marburg virus Rwanda outbreak (2024) — containment with emergency vaccines.
- PM-ABHIM implementation — 70%+ of district labs operationalised by 2024.
- Project BIRD (ICMR) — biobanking for pathogen readiness.
- National One Health Mission rolled out (2024).
- Bharat Biotech's Chandipura/Nipah vaccine candidates under development (2024-25).
- AI Action Summit, Paris (Feb 2025) — AI-for-pandemic flagged.
- India Semiconductor Mission — diagnostic chip manufacturing.
- DeepTech Policy 2024 — biosensors, vaccine manufacturing.
- National Quantum Mission (2024) — quantum sensors for pathogen detection.
- Chandrayaan-4 plan and Gaganyaan progress — space-biology research in microbial resilience.
UPSC Relevance
GS Paper III — Science & Technology / Health
- Pandemic preparedness, Disease X, vaccines.
GS Paper II — Governance / International Relations
- WHO reforms, IHR, Pandemic Agreement.
GS Paper III — Disaster Management
- DM Act 2005, multi-sectoral coordination.
GS Paper II — Social Justice
- Equitable access, PDS-style vaccine distribution.
GS Paper IV — Ethics
- Vaccine nationalism; prioritising vulnerable; clinical-trial ethics.
Prelims pointers — WHO R&D Blueprint Priority Pathogens, INSACOG, PM-ABHIM (Rs 64,180 crore), IHR 2005, Pandemic Agreement, Mpox PHEIC 2024, One Health Mission, Ayushman Bharat Digital Mission, NIV Pune BSL-4.
Interview probes — lessons from COVID; pandemic treaty sovereignty issues; One Health; district-level preparedness; mpox vs COVID response.
Disease X is not a matter of "if" but "when". The test of a public-health state is whether its next wave arrives faster than its last bureaucratic memo. India is building that muscle — slowly but deliberately.